Abstract: The present invention provides a hydrogel comprising a poly(N-isopropylacrylamide) cross-linked hyaluronic acid. The present invention also provides a method of synthesizing a hydrogel comprising poly(N-isopropylacrylamide) cross-linked hyaluronic acid, which comprises (a) synthesizing methacrylated hyaluronic acid; and (b) copolymerizing methacrylated hyaluronic acid with N-isopropylacrylamide.

Abstract: Disclosed herein is a three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes, as well as a process for preparing the same. The three-dimensional culture, which was found to mimic the biological characteristics of articular chondrocytes that undergo terminal differentiation in vivo, can be used as a tool in the studies of the molecular and cellular mechanisms of osteoarthritis, and in the screening of candidate drugs for use in treatment of a disorder associated with articular chondrocytes.

Abstract: A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function.

Abstract: A short term controlled release composition which comprises poly(lactic-co-glycolic acid) cross-linked alendronate (PLGA-ALN) is provided. The PLGA-ALN is constructed into 3D scaffolds (PLGA-ALN-3D) with pores size of 150-300 ?m and average porosity of 85%, or microspheres (PLGA-ALN-M) with 50-100 ?m in diameter. The released alendronate concentration is in the range of 5×10?7 M to 5×10?8 M.

Abstract: A single-ended signaling system in which transmitted and returned signal currents are enabled to flow substantially parallel to one another and thereby maintain a substantially uniform impedance along the length of a single-ended signal conductor. A reference plane is disposed substantially parallel to a single-ended signaling conductor and coupled to the signaling conductor within a signal-receiving IC and to signaling supply voltage nodes within a signal-transmitting IC. By this arrangement, an signal current flowing to or from the receiving IC via the signaling conductor is conducted to the reference plane, thereby enabling a signal-return current to flow back to or back from the transmitting IC along a single path that is substantially parallel to the signal conductor.

Abstract: Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.

Abstract: Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.

Abstract: An isoxazole derivative is provided. The isoxazole derivative has following formula: wherein R1, R2, R3, R4 and R5, independently, include hydrogen, hydroxy or C1-C12 alkoxy optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy. The invention also provides a pharmaceutical composition for treatment of osteoporosis and cancer including an isoxazole derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a bisphosphonates and synthetic polymeric carriers to form a sustained release system. The present invention also provides a method for preparing a sustained release system, comprising activation of the synthetic polymeric carriers and the cross linking reaction. The present invention further provides methods for enhancing stem cell differentiation into osteogenic lineage and chondrogenic lineage, which comprise culturing a population of stem cells in specific micro-environments.

Abstract: An auxiliary tank for the flush toilet, wherein the one end of the pulling line is connected with a floating ball of the auxiliary tank, then the line is wound from a lower pulley to an upper pulley, and passed through a penetrated hole of a hollow tube, finally the other end of the line is connected with a extension arm in a main tank. When the water level in the main tank is full, the extension arm of the water refilling pipe will be hold by the pulling line which is connected with the floating ball, to limit the refilling water into the main tank from the water refilling pipe but from the auxiliary tank. In the light of above, the flush of the toilet is still able to be operated even at the time of water outage or shutting off the water valve. In addition, the water that refills into the auxiliary tank is the recycling water.

Abstract: A method for displaying pictures during a digital picture slide show includes receiving a plurality of pictures, determining display characteristics of the plurality of pictures according to weighting values of the plurality of pictures, and displaying the plurality of pictures according to the display characteristics of the plurality of pictures.

Abstract: A novel nanoparticle and use thereof were provided in the present invention. In particular, the nanoparticle is used for delivering therapeutic component, such as oligonucleotide and hydrophobic drug.

Abstract: A controlled release system and manufacturing method is provided. The method comprises providing a first aqueous solution containing a hydrophilic drug and an alkaline agent, providing an organic solution containing a hydrophobic molecule, providing a second aqueous solution containing a hydrophilic surfactant, mixing the first hydrophilic solution with the organic solution to form a first emulsion, and mixing the first emulsion with a second aqueous solution to form a second emulsion containing delayed-release microsphere.

Abstract: The present invention provides a method for producing a controlled release microsphere with mean average size greater than 50 ?m, comprising preparing a water-in-oil (w/o) emulsion comprising an inner aqueous layer containing a pharmaceutically effective amount of a biologically active polypeptide with activity similar to parathyroid hormone, and an oil layer containing a polymer substance of poly (lactic-co-glycolic acid) (PLGA), then adding the w/o emulsion into aqueous polyvinyl alcohol (PVA) solution to form a water-in-oil-in-water (w/o/w) double emulsion and then desorbing the solvent in the oil layer. The present invention also provides a controlled release microsphere prepared by the method and use thereof.

Abstract: The present invention provides a method for preparing a composition comprising porous ceramic, comprising the following steps: (a) synthesizing poly(N-isopropylacrylamide-co-methacrylic acid) (p(NIPAAM-MAA)) or similar thermo-response compound thereof; (b)mixing a dispersant with hydroxyapatite or calcium phosphate salt; (c) mixing the p(NIPAAM-MAA) of the step (a) or similar thermo-response compound thereof with water to obtain a hydrogel solution; (d) mixing the hydrogel solution of the step (c) and product of the step (b) to produce a mixture; (e) adding macromolecular particles to the mixture of the step (d) and stirring to produce a slurry; (f) filling the slurry of the step (e) into a template slot; and disposing the template slot filling with the slurry of the step (f) on a crucible, then proceeding high temperature sinter in a furnace to form the composition comprising porous ceramic.

Abstract: An auxiliary tank for the flush toilet, wherein the one end of the pulling line is connected with a floating ball of the auxiliary tank, then the line is wound from a lower pulley to an upper pulley, and passed through a penetrated hole of a hollow tube, finally the other end of the line is connected with a extension arm in a main tank. When the water level in the main tank is full, the extension arm of the water refilling pipe will be hold by the pulling line which is connected with the floating ball, to limit the refilling water into the main tank from the water refilling pipe but from the auxiliary tank. In the light of above, the flush of the toilet is still able to be operated even at the time of water outage or shutting off the water valve. In addition, the water that refills into the auxiliary tank is the recycling water.

Abstract: The present invention relates to a hydrophilic drug and ?-tricalcium phosphate (?-TCP) coating on a surface area of biopolymer matrix to form a sustained release system. The present invention also provides a method for preparing a sustained release system, comprising providing a surface are of biopolymer matrix coated with a hydrophilic drug and ?-TCP.

Abstract: A method for treating early-stage osteoarthritis in an animal is provided. The method comprises delivery of a therapeutically effective amount of a parathyroid hormone (PTH) or a PTH derived substance to an affected joint cavity of the patient. Methods for inhibiting articular chondrocytes apoptosis and for inhibiting a degenerative process of articular chondrocytes in an afflicted animal are also provided.

Abstract: A method for treating and/or inhibiting arthritis is provided. The method includes administering an effective amount of a composition including a parathyroid hormone and a pharmaceutically acceptable carrier or salt to a subject with arthritis. Additionally, a method for inhibiting and/or rescuing terminal differentiation of cells is also provided.

Abstract: An isoflavone derivative is provided. The isoxazole derivative has following formula: wherein R1 and R2, independently, include C1-C12 alkyl optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy, and R3 includes hydrogen, hydroxy or C1-C12 alkoxy optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy. The invention also provides a pharmaceutical composition for treatment of osteoporosis including an isoflavone derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.